Ayad Sarah, Gergis Kirolos, Elkattawy Sherif, Mirza Noreen, Abdelazeem Basel, Patel Latika, Remolina Carlos
Internal Medicine, Rutgers-New Jersey Medical School/Trinitas Regional Medical Center, Elizabeth, New Jersey, USA.
Internal Medicine, McLaren Health Care, Flint, Michigan, USA.
Eur J Case Rep Intern Med. 2021 Jul 15;8(7):002706. doi: 10.12890/2021_002706. eCollection 2021.
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical manifestations are diverse and can vary from mild respiratory symptoms to severe hypoxic respiratory failure. In severe cases, infection can cause gastrointestinal, renal, cardiac, neurological and haematological complications and result in multi-organ failure. There are very few reports of parapneumonic effusion in patients with COVID-19. We describe two patients with COVID-19 who had loculated empyema and discuss the clinical course and therapeutic options.
The clinical manifestations of COVID-19 vary from mild to severe disease and can result in multi-organ failure.Pleural empyema is usually treated with a combination of antibiotics and surgical drainage of the pleural cavity.
2019冠状病毒病（COVID-19）由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起。其临床表现多样，可从轻微呼吸道症状到严重的低氧性呼吸衰竭。在严重病例中，感染可导致胃肠道、肾脏、心脏、神经和血液系统并发症，并导致多器官功能衰竭。关于COVID-19患者并发肺炎旁胸腔积液的报道非常少。我们描述了两名患有局限性脓胸的COVID-19患者，并讨论了临床病程和治疗选择。
COVID-19的临床表现从轻症到重症不等，可导致多器官功能衰竭。胸腔脓胸通常采用抗生素联合胸腔手术引流进行治疗。
